Characteristics of gastric precancerous conditions and *Helicobacter pylori* infection among dyspeptic patients in north-eastern Iran: is endoscopic biopsy and histopathological assessment necessary?

Abbas Esmaeilzadeh1†, Ladan Goshayeshi1,2†, Robert Bergquist3,4, Lida Jarahi5, Alireza Khooei6, Alireza Fazeli7, Hooman Mosannen Mozafari1, Ali Bahari1, Mohammad Bagher Oghazian8* and Benyamin Hoseini9,10*

Abstract

**Background:** Early detection and appropriate treatment of precancerous, mucosal changes could significantly decrease the prevalence of life-threatening gastric cancer. Biopsy of the normal-appearing mucosa to detect *Helicobacter pylori* and these conditions is not routinely obtained. This study assesses the prevalence and characteristics of *H. pylori* infection and precancerous conditions in a group of patients suffering from chronic dyspepsia who were subjected to gastric endoscopy and biopsy mapping.

**Methods:** This cross-sectional study included dyspeptic patients, not previously treated for *H. pylori*, undergoing esophagogastroduodenoscopy (EGD) with their gastric endoscopic biopsies obtained for examination for evidence of *H. pylori* infection and precancerous conditions. Demographic and clinical data on the gender, smoking, opium addiction, alcohol consumption, medication with aspirin, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) and family history of cancer were collected by interviewing the patients and evaluating their health records. The cohort examined consisted of 585 patients with a mean (SD) age of 48.0 (14.46) years, 397 (67.9%) of whom were women.

* Correspondence: mohammadbagher_oghazian@yahoo.com; HoseiniB1@nums.ac.ir
†Abbas Esmaeilzadeh and Ladan Goshayeshi contributed equally as joint lead authors.
8Department of Internal Medicine, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
9Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

Gastric cancer is still a major worldwide problem, ranking fifth for incidence and third for cancer-related mortality [1–3]. According to GLOBOCAN 2018, gastric carcinoma is the second most common cancer in Iran and the 5-year prevalence is 19.22 per 100,000 [2]. Chronic atrophic gastritis and intestinal metaplasia are considered precancerous conditions and they constitute the background, against which dysplasia and more serious histological changes may occur [4]. Intestinal-type gastric adenocarcinoma represents the final outcome of the inflammation–atrophy–metaplasia–dysplasia–carcinoma sequence [5]. Even though early recognition and treatment is possible, most cases are diagnosed at a late stage and thus a large number of patients diagnosed with gastric cancer die of the disease [1]. Early detection and treatment, primarily by endoscopy rather than invasive surgery, is recommended [6, 7].

Multiple risk factors have been linked to the multistep progression from precancerous conditions to gastric cancer [8–10]. Helicobacter pylori infection plays a pivotal role in this progression, and a recent meta-analysis indicates that testing and treating this infection when found is associated with a reduced incidence of gastric cancer [11, 12]. This indicates the importance of knowing the distribution and prevalence of H. pylori infections and precancerous conditions and related risk factors, including the strategies suitable for lowering the incidence of gastric cancer. Although this would clearly help to prevent gastric cancer, few studies on the incidence of gastric precancerous conditions and H. pylori infection have been published in Iran. However, Ajar-Darkosh et al. [13] have found prevalence of H. pylori infection, intestinal metaplasia, gastric atrophy and dysplasia in 64.5, 19.8, 12.8 and 3.2%, respectively, among chronically dyspeptic patients aged ≥40 years. They recommend upper endoscopy and gastric mapping sampling in intermediate-risk to high-risk areas. Another study in Ardabil province [14], which has a high rate of gastric cancer, found that atrophic gastritis, reactive atypia and intestinal metaplasia are common in the antrum, corpus and cardia of the stomach and they therefore recommend endoscopic screening for precancerous conditions.

Esophagogastroduodenoscopy (EGD) is commonly performed when evaluating patients with dyspepsia [15]. In many cases with normal-appearing mucosa, H. pylori and precancerous conditions can still be present in the stomach, and a reliable diagnosis is therefore important. In the absence of endoscopically visible lesions, biopsies from the stomach would contribute to diagnosing most H. pylori-related inflammatory and precancerous gastric lesions, which would be misdiagnosed without access to biopsies [16].

The American Gastroenterological Association (AGA) currently recommends biopsy even from normal-appearing mucosa for the detection of H. pylori infection if previously unknown in the patient [15, 17]. However, to our knowledge, there are no clinical standards or guidelines for the performance of biopsies with respect to H. pylori and precancerous conditions of normal-appearing gastric mucosa in Iranian patients. The additional expense incurred by the need for obtaining and interpreting more biopsies from normal mucosa [18] may be cancelled out by the lower numbers of people developing gastric cancer. Early diagnosis of precancerous conditions and H. pylori infection would no doubt lead to an effective approach which would allow the early detection of gastric cancer, especially in high-risk areas like Iran. To that end, this study would assessed the prevalence and characteristics of H. pylori infection and precancerous conditions in patients with normal and
abnormal-appearing mucosa undergoing EGD with dyspepsia as the sole indication.

Material and methods

Study summary

We conducted a cross-sectional study from 2015 to 2017 based on clinical data, bacterial findings and histological classification of the gastric mucosa in a set of patients with dyspepsia at the Gastroenterology Clinic of Emam Reza Hospital, a tertiary referral hospital affiliated with Mashhad University of Medical Sciences (MUMS). The inclusion/exclusion process was done as shown in Fig. 1.

Participants

During the three study years, patients aged > 18 years with dyspepsia, consistent with the Rome III criteria [19], which include one or more of postprandial fullness, early satiation, epigastric pain and/or burning, and thus eligible for EGD (n = 701), were enrolled. Patients were excluded if they had any history of partial/total gastrectomy or previous therapy for *H. pylori* infection. At this point, 16 patients opted out of the study for unknown reasons leaving 654 for the next step. However, EGD was only performed on 633 patients since 21 were unwilling to undergo the examination. A further 48 patients were excluded for various reasons (Fig. 1) resulting in 585 participants in the study.

Data gathering

Demographic data and clinical characteristics, including data on age, gender, past medical history (diabetes and hypertension in particular), tobacco use (daily smoking), alcohol use (daily drinker), opium addiction (daily user > 6 months), taking ≥500 mg of aspirin for > 1 month or other non-steroidal anti-inflammatory drugs (NSAIDs), family history of cancer (especially in first-degree relatives (FDRs) and/or second-degree relatives (SDRs) were collected by interviewing the patients and evaluating their health records before the EGD step.

Histopathology

Endoscopic biopsies were fixed in adequately buffered formalin (10%) overnight and subsequently routinely processed. All fragments were embedded in one paraffin block, multiple serial sections were obtained and all stained by routine hematoxylin/eosin and Giemsa stains. The slides were examined by two pathologists and in case of any diagnostic disagreement, other colleagues were asked to review the slides. Furthermore, macro-endoscopic features observed during the gastric inspection were also reviewed.

Precancerous conditions refer to a variety of conditions in which changes in stomach cells make them more prone into cancer. In our study, these included mucosal atrophy, intestinal metaplasia, dysplasia and mucosa with abnormal gastric biopsy. Gastric atrophy is considered if there are loss of gastric glands, either together with pure (non-metaplastic) or associated with pyloric or intestinal metaplasia (metaplastic type). The

---

**Fig. 1 Flow diagram of patient recruitment**

- Patients eligible for EGD with dyspepsia since ≥3 year (n= 701)
  - Excluded (n= 47) due to:
    - partial or total gastrectomy (n= 8);
    - previous curative therapy for *H. pylori* infection (n= 23); or
    - declining participation (n= 16)
  - Included in the study (n= 654)
    - EGD performed (n= 633)
      - Excluded (n= 48) due to:
        - unavailable laboratory data (n= 13);
        - diagnosis of gastric cancer (n= 16);
        - diagnosis of other cancers (n= 12); or
        - lost pathology data (n= 7)
  - Analyzed (n= 585)
degree of atrophy is graded as mild, moderate or severe; however, in this study, all types of atrophy was considered regardless of severity. Gastric dysplasia, regarded as a combination of architectural atypia (glandular crowding, budding and branching) and cytologic atypia (cellular overlapping, hyperchromasia of the nuclei, pseudostratification, pleomorphism, dispolarity, increased mitosis and lack of surface maturation), was classified as adenomatous (intestinal) or foveolar (gastric). Regarding the extent of these changes, dysplasia was graded as low or high; however, all types of dysplasia were considered regardless of severity.

Expected outcomes
The primary focus was on finding precancerous conditions and H. pylori infection. A secondary focus was to evaluate potential associations between the histopathological examinations and the responses collected.

Statistical analysis
The chi square test was used to determine differences in the categorical variables. The Shapiro–Wilk test was used to examine the degree of data normality, while T-test, ANOVA, Mann–Whitney or Kruskal–Wallis tests were used to investigate the normality distribution of the data, i.e. to identify potential, significant differences between independent variables. Multivariable logistic regression analysis with backward stepwise model was used to ascertain the statistical significance of the association between precancerous conditions on the one hand and demographic data, clinical characteristics and H. pylori presence on the other. A two-tailed p-value of less than 0.05 was considered statistically significant. The analyses were performed using SPSS statistics (version 20.0, IBM Corp., Armonk, NY, USA).

Results
Demographic data, clinical characteristics including H. pylori status and histological patterns from the 585 patients (67.9% women) were analyzed (Table 1 and Table 2). The mean (±SD) age of the participants was 48.0 (±14.46) years. Also, 146 (25.0%) patients were addicted to opium or methamphetamine. Alcohol consumption was reported in 50 (8.5%) of the patients, while 173 (29.6%) regularly used NSAIDs and 88 (15.0%) aspirin. Histologic findings in endoscopic biopsies from the patients revealed that the prevalence of intestinal metaplasia, gastric atrophy and gastric dysplasia was 15.2, 12.6, and 7.9%, respectively. H. pylori infection rates were found in as many as 80.2% of the patients, with a particularly high prevalence among those aged 40–60 years. Opium addiction indicated higher H. pylori infection rates, while the situation was the opposite with respect to alcohol consumption (OR 1.98, 95% CI 1.11–3.52 and OR 0.49, 95% CI 0.26–0.92, respectively).

Based on multivariable logistic regression analysis, increased age and positive H. pylori infection indicated a significant association with precancerous conditions. In contrast, NSAID consumption showed a negative association with investigated outcomes (Table 3).

For 121 patients (20.7% of all), the EGD examination revealed normal gastric mucosa; however, for more than half (68/121–56.2%) of these patients, the histological evaluation showed H. pylori infection and also signs of atrophic mucosa, intestinal metaplasia and dysplasia in 1.7, 4.1 and 1.7%, respectively.

Table 1 Basic characteristics of the study participants

| Common risk factors        | Metaplasia | Atrophy | Dysplasia | Abnormal gastric biopsy | No pathological finding | Total |
|----------------------------|------------|---------|-----------|-------------------------|------------------------|-------|
| Age (years)                |            |         |           |                         |                        |       |
| ≤ 40                       | 5 (2.3)    | 2 (1.0) | 2 (1.0)   | 59 (27.4)               | 147 (68.3)             | 215   |
| 41–50                      | 19 (15.3)  | 13 (10.5)| 16 (12.9) | 16 (12.9)               | 60 (48.4)              | 124   |
| 51–60                      | 24 (19.5)  | 22 (17.9)| 9 (7.3)   | 16 (13.0)               | 52 (42.3)              | 123   |
| ≥ 61                       | 41 (33.3)  | 37 (30.1)| 19 (15.4)| 12 (9.7)                | 14 (11.4)              | 123   |
| Sex                        |            |         |           |                         |                        |       |
| Female                     | 52 (13.1)  | 41 (10.3)| 32 (8.1)  | 78 (19.6)               | 194 (48.9)             | 397   |
| Male                       | 37 (19.7)  | 33 (17.5)| 14 (7.4)  | 25 (13.3)               | 79 (42.0)              | 188   |
| H. pylori infection         | 83 (17.7)  | 68 (14.5)| 42 (8.9)  | 52 (11.1)               | 224 (47.8)             | 469   |
| Smoking                    | 20 (17.8)  | 17 (15.2)| 9 (8.0)   | 16 (14.3)               | 50 (44.6)              | 112   |
| NSAID use                  | 13 (7.5)   | 11 (6.3) | 6 (3.5)   | 27 (15.6)               | 116 (67.0)             | 173   |
| Aspirin                    | 8 (9.1)    | 13 (14.8)| 6 (6.8)   | 15 (17.0)               | 46 (52.3)              | 88    |
| Addiction (opium and/or methamphetamine) | 35 (24.0) | 30 (20.5)| 17 (11.6)| 19 (13.0)               | 45 (30.8)              | 146   |
| Alcohol consumption        | 6 (12.0)   | 6 (12.0) | 3 (6.0)   | 8 (16.0)                | 27 (54.0)              | 50    |

NSAID, nonsteroidal anti-inflammatory drug
Table 2: Association of precancerous conditions, abnormal gastric biopsy, atrophy, metaplasia and dysplasia with demographic and clinical characteristics of the dyspeptic patients

| Categorical variable                        | Precancerous conditions (n = 585) | Abnormal gastric biopsy (n = 585) | Atrophy (n = 585) | Metaplasia (n = 585) | Dysplasia (n = 585) |
|--------------------------------------------|-----------------------------------|----------------------------------|-------------------|---------------------|---------------------|
|                                            | Yes (n = 122)                    | No (n = 463)                    | P-value           | Yes (n = 74)        | No (n = 511)        | P-value           | Yes (n = 46)        | No (n = 539)        | P-value           |
| Age (years)                                |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| <= 40                                      |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
|                                            | 7 (5.7)                           | 208 (44.9)                      | 0.001             | 2 (2.7)             | 213 (41.7)          | 0.001             | 5 (5.6)             | 210 (42.3)          | 0.001             |
|                                            |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
| 41–50                                      |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
|                                            | 33 (27.1)                        | 91 (19.7)                       |                   | 13 (17.6)           | 111 (21.7)          |                   | 19 (21.3)           | 105 (21.2)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
| 51–60                                      |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
|                                            | 34 (27.9)                        | 89 (19.2)                       |                   | 22 (29.7)           | 101 (19.8)          |                   | 24 (27.0)           | 99 (20.0)           |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
| > = 61                                     |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
|                                            | 48 (39.3)                        | 75 (16.2)                       |                   | 37 (50.0)           | 86 (16.8)           |                   | 41 (46.1)           | 82 (16.5)           |                   |
| Sex                                        |                                   |                                  |                   |                     |                     |                   |                   |                     |                   |
|                                            | Female (n = 397)                 |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | 76 (62.3)                        | 321 (69.3)                      | 0.15              | 41 (55.4)           | 356 (69.7)          | 0.01              | 52 (58.4)           | 345 (69.6)          | 0.04              |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Male (n = 188)                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | 46 (37.7)                        | 142 (30.7)                      |                   | 25 (24.3)           | 163 (33.8)          |                   | 33 (44.6)           | 155 (30.3)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| Smoking                                    |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 112)                    |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | 25 (20.5)                        | 87 (18.8)                       | 0.69              | 17 (23.0)           | 95 (18.6)           | 0.37              | 20 (22.5)           | 92 (18.5)           | 0.39              |
|                                            | No (n = 473)                     |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | 97 (79.5)                        | 376 (81.2)                      |                   | 87 (84.5)           | 386 (80.1)          |                   | 57 (77.0)           | 416 (81.4)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| Addiciton*                                 |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 146)                    |                                  | 0.003             | 30 (40.5)           | 116 (22.7)          | 0.001             | 35 (39.3)           | 111 (22.4)          | 0.001             |
|                                            | No (n = 439)                     |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | 79 (64.8)                        | 360 (77.8)                      |                   | 44 (49.5)           | 395 (77.3)          |                   | 54 (60.7)           | 385 (77.6)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| Alcohol consumption                        |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 50)                     |                                  | 0.85              | 8 (8.1)             | 44 (8.6)            | 0.88              | 6 (6.7)             | 44 (8.9)            | 0.86              |
|                                            | No (n = 535)                     |                                  |                   | 95 (92.2)           | 440 (91.3)          |                   | 68 (91.9)           | 467 (91.4)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| NSAID use                                  |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 173)                    |                                  | 0.001             | 27 (26.2)           | 146 (30.3)          | 0.47              | 11 (14.9)           | 162 (31.7)          | 0.003             |
|                                            | No (n = 412)                     |                                  |                   | 76 (73.8)           | 336 (69.7)          |                   | 63 (85.1)           | 349 (68.3)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| Aspirin use                                |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 88)                     |                                  | 0.39              | 15 (14.6)           | 73 (15.1)           | 1.0               | 13 (17.6)           | 75 (14.7)           | 0.51              |
|                                            | No (n = 497)                     |                                  |                   | 107 (87.7)          | 390 (84.2)          |                   | 61 (82.4)           | 436 (85.3)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| Diabetes (types I and II)                  |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 99)                     |                                  | 0.46              | 20 (164)            | 79 (17.1)           | 1.0               | 13 (12.6)           | 86 (17.8)           | 0.25              |
|                                            | No (n = 486)                     |                                  |                   | 102 (836)          | 384 (82.9)          |                   | 90 (87.4)           | 396 (82.2)          |                   |
|                                            |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
| H. pylori infection                        |                                   |                                  |                   |                     |                     |                   |                     |                     |                   |
|                                            | Yes (n = 469)                    |                                  | 0.048             | 114 (93.4)          | 355 (76.7)          | 0.001             | 52 (50.5)           | 417 (86.5)          | 0.001             |
|                                            | No (n = 116)                     |                                  |                   | 8 (66)             | 108 (23.3)          |                   | 51 (49.5)           | 65 (13.5)           |                   |
Table 2 Association of precancerous conditions, abnormal gastric biopsy, atrophy, metaplasia and dysplasia with demographic and clinical characteristics of the dyspeptic patients (Continued)

| Categorical variable | Precancerous conditions (n = 585) | Abnormal gastric biopsy (n = 585) | Atrophy (n = 585) | Metaplasia (n = 585) | Dysplasia (n = 585) |
|----------------------|----------------------------------|----------------------------------|------------------|--------------------|---------------------|
|                      | Yes (n = 122)                  | No (n = 463)                    | Yes (n = 74)     | No (n = 511)       | Yes (n = 89)        |
|                      | n (%)                          | n (%)                          | n (%)            | n (%)              | n (%)               |
| Dyspepsia pattern    |                                 |                                 |                  |                    |                     |
| EPS (n = 245)        | 50 (41.0)                      | 195 (42.1)                     | 2 (2.7)          | 119 (23.3)         | 5 (5.6)             |
| Flatulence (n = 143) | 30 (24.6)                      | 113 (24.4)                     | 18 (24.3)        | 125 (24.5)         | 22 (24.7)           |
| Early satiation (n = 48) | 11 (90.0)                  | 37 (8.0)                       | 7 (9.5)          | 41 (8.0)           | 7 (7.9)             |
| PF (n = 48)          | 10 (8.2)                       | 38 (8.2)                       | 9 (8.1)          | 42 (8.2)           | 8 (9.0)             |
| Reflux (n = 101)     | 21 (17.2)                      | 80 (173)                       | 12 (16.2)        | 89 (17.4)          | 15 (16.9)           |
| Endoscopic findings  |                                 |                                 |                  |                    |                     |
| Normal (n = 121)     | 5 (4.1)                        | 116 (25.0)                     | 2 (2.7)          | 119 (23.3)         | 5 (5.6)             |
| Erythema (n = 176)   | 23 (18.8)                      | 153 (33.1)                     | 10 (13.5)        | 166 (32.5)         | 12 (13.5)           |
| M o/s (n = 151)      | 33 (27.1)                      | 118 (25.9)                     | 18 (24.3)        | 133 (26.0)         | 20 (22.5)           |
| Erosion (n = 68)     | 18 (14.7)                      | 50 (10.8)                      | 11 (14.9)        | 57 (11.2)          | 17 (19.1)           |
| GDU (n = 36)         | 21 (17.2)                      | 15 (3.3)                       | 12 (16.2)        | 24 (4.7)           | 16 (18.0)           |
| Atrophy (n = 33)     | 22 (18.1)                      | 11 (2.4)                       | 21 (28.4)        | 12 (2.3)           | 19 (21.3)           |
| Endoscopic findings  |                                 |                                 |                  |                    |                     |
| Normal (n = 397)     | 89 (73.0)                      | 308 (66.9)                     | 50 (67.6)        | 347 (67.9)         | 61 (68.5)           |
| GC (n = 69)          | 12 (99)                        | 57 (123)                       | 13 (12.6)        | 56 (11.6)          | 7 (9.5)             |
| IC (n = 1)           | 0 (0.0)                        | 1 (0.2)                        | 1 (1.0)          | 0 (0.0)            | 0 (0.0)             |
| CC (n = 81)          | 17 (139)                       | 64 (138)                       | 5 (4.9)          | 76 (15.8)          | 14 (18.9)           |
| OC (n = 12)          | 2 (16)                         | 10 (2.2)                       | 2 (1.9)          | 10 (2.1)           | 2 (1.9)             |
| LC (n = 1)           | 1 (08)                         | 13 (2.8)                       | 1 (1.4)          | 13 (2.5)           | 1 (1.1)             |
| PC (n = 11)          | 1 (08)                         | 10 (2.2)                       | 1 (1.4)          | 10 (2.0)           | 1 (1.1)             |
| RHNGC                |                                 |                                 |                  |                    |                     |
| None (n = 504)       | 112 (91.8)                     | 392 (84.7)                     | 66 (89.2)        | 438 (85.7)         | 423 (85.3)          |
| Breast (n = 34)      | 2 (16)                         | 32 (6.9)                       | 8 (7.8)          | 26 (5.4)           | 1 (1.4)             |
| Cervical (n = 6)     | 1 (08)                         | 5 (1.1)                        | 2 (1.9)          | 4 (0.8)            | 1 (1.4)             |

Note: P-values are indicated below each group comparison.
| Categorical variable | Precancerous conditions (n = 585) | P-value | Abnormal gastric biopsy (n = 585) | P-value | Atrophy (n = 585) | P-value | Metaplasia (n = 585) | P-value | Dysplasia (n = 585) | P-value |
|----------------------|-----------------------------------|---------|-----------------------------------|---------|------------------|---------|---------------------|---------|---------------------|---------|
| Yes (n = 122)        | No (n = 463)                      |         | Yes (n = 103)                     | No (n = 482) | Yes (n = 74) | No (n = 511) | Yes (n = 89) | No (n = 496) | Yes (n = 46) | No (n = 539) |
| Ovarian (n = 6)      | 2 (1.6)                           |         | 2 (1.9)                           | 4 (0.8)   | 2 (2.7)         | 4 (0.8)   | 2 (2.2)             | 4 (0.8)   | 1 (2.2)             | 5 (0.9)  |
| Bladder (n = 4)      | 1 (0.8)                           |         | 2 (1.9)                           | 2 (0.4)   | 1 (1.4)         | 3 (0.6)   | 1 (1.1)             | 3 (0.6)   | 0 (0.0)             | 4 (0.7)  |
| Kidney (n = 6)       | 1 (0.8)                           |         | 3 (2.9)                           | 2 (0.4)   | 1 (1.4)         | 4 (0.8)   | 0 (0.0)             | 5 (1.0)   | 1 (2.2)             | 4 (0.7)  |
| Haematological (n = 12) | 0 (0.0)                          |         | 2 (1.9)                           | 10 (2.1)  | 0 (0.0)         | 12 (2.4)  | 0 (0.0)             | 12 (2.4)  | 0 (0.0)             | 12 (2.2) |
| Pulmonary (n = 14)   | 3 (2.5)                           |         | 3 (2.9)                           | 11 (2.3)  | 2 (2.7)         | 12 (2.3)  | 3 (3.4)             | 11 (2.2)  | 0 (0.0)             | 14 (2.6) |

| Continuous variable | mean ± SD | mean ± SD | P-value | mean ± SD | mean ± SD | P-value | mean ± SD | mean ± SD | P-value | mean ± SD | mean ± SD | P-value |
|---------------------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|-----------|-----------|---------|
| Age (years)         | 57.8 ± 13.1 | 45.4 ± 13.7 | 0.001   | 41.6 ± 12.6 | 49.3 ± 14.5 | 0.001   | 61.0 ± 12.6 | 46.1 ± 13.7 | 0.001   | 59.4 ± 13.2 | 45.9 ± 13.7 | 0.001   |
| Haemoglobin (Hgb)   | 13.3 ± 16  | 13.3 ± 15  | 0.48    | 13.4 ± 1.5  | 13.3 ± 1.5  | 0.62    | 12.9 ± 1.5  | 13.4 ± 1.5  | 0.14    | 13.1 ± 1.6  | 13.4 ± 1.5  | 0.12    |
| 25(OH)D3 vitamin    | 21.7 ± 13.0 | 18.1 ± 11.2 | 0.002   | 18.0 ± 11.5  | 19.0 ± 11.7  | 0.27    | 208 ± 12.4  | 18.5 ± 11.6  | 0.14    | 223 ± 13.7  | 18.2 ± 11.2  | 0.004   |

EPSP: Epigastric pain syndrome; M o/s: Mucosal oedema/swelling; PF: Postprandial fullness; GDU: Gastric or duodenal ulcer; FHGC: Family history of gastro-intestinal cancer; FHNGC: Family history of non-gastro/intestinal cancer; GC: gastric cancer; IC: Intestinal cancer; CC: Colon cancer; OC: Oesophagus cancer; LC: Liver cancer; PC: Pancreas cancer. *Addiction = opium and/or methamphetamine
have been missed without access to biopsies. The association with dysplasia is more important compared to other conditions. Consequently, it is necessary to apply endoscopic resection once high-grade dysplasia is observed. Although \textit{H. pylori} eradication is advantageous when intestinal metaplasia is identified, follow-up endoscopic examinations should be considered in patients with intestinal metaplasia and in the older age range to detect more progressive conditions [24]. The findings also indicated that precancerous conditions could be found in normal-appearing mucosa. Considering that precancerous conditions may become stomach cancer, detecting them especially in dyspeptic patients older than 40 years with \textit{H. pylori} infection and opium addiction is regarded as a high priority.

\textit{H. pylori} infection rates are very high in different parts of Iran, with a prevalence rate ranging from 69 to 89%, and they do increase with age [25–27]. Population-based studies have reported that > 80% of adults aged ≥40 years are infected and that 64.5% of these infections occurred in dyspeptic patients [13]. Our study revealed a similar high rate (80.2%).

The pathogenesis of gastric cancer is multifactorial and associated with a degree of precancerous conditions [23, 28, 29]. Gastric atrophy, dysplasia, and intestinal

---

**Table 3** Association between precancerous conditions and variables investigated

| Type of pathology     | Variation        | Univariate logistic regression | Multivariate logistic regression |
|----------------------|------------------|-------------------------------|---------------------------------|
|                      |                  | OR (95% CI)                    | P-value                         | OR (95% CI)                     | P-value |
| Precancerous conditions | Age ≤40 years    | Reference                      | –                               | Reference                      | –       |
|                      | Age between 41 and 50 years | 10.77 (4.59–25.26)         | 0.001                          | 10.78 (4.54–25.59)            | 0.001   |
|                      | Age between 51 and 60 years | 11.35 (4.84–26.57)         | 0.001                          | 9.88 (4.18–23.35)             | 0.001   |
|                      | Age ≥61 years     | 19.01 (8.24–43.86)           | 0.001                          | 18.53 (7.94–43.26)            | 0.001   |
|                      | NSAID consumption | 0.34 (0.20–0.58)             | 0.001                          | 0.34 (0.19–0.60)              | 0.001   |
|                      | \textit{H. pylori} infection | 4.33 (2.05–9.16)         | 0.001                          | 4.01 (1.83–8.78)              | 0.001   |
| Abnormal gastric biopsy | Age between 41 and 50 years | 2.55 (1.39–4.67)         | 0.002                          | 2.32 (1.22–4.39)              | 0.01    |
|                      | Age between 51 and 60 years | 2.52 (1.38–4.63)         | 0.003                          | 2.16 (1.14–4.08)              | 0.01    |
|                      | Age ≥61 years     | 3.49 (1.79–6.81)            | 0.001                          | 3.28 (1.63–6.60)              | 0.001   |
|                      | \textit{H. pylori} infection | 6.29 (3.94–10.01)         | 0.001                          | 5.92 (3.67–9.55)              | 0.001   |
| Atrophy              | Age between 41 and 50 years | 12.47 (2.76–56.25)        | 0.001                          | 11.96 (2.64–52.20)            | 0.001   |
|                      | Age between 51 and 60 years | 23.19 (5.35–100.56)       | 0.001                          | 20.19 (4.64–87.90)            | 0.001   |
|                      | Age ≥61 years     | 45.82 (10.80–194.30)        | 0.001                          | 43.29 (10.16–184.33)          | 0.001   |
|                      | NSAID consumption | 0.37 (0.19–0.73)            | 0.004                          | 0.40 (0.20–0.82)              | 0.012   |
|                      | \textit{H. pylori} infection | 3.1 (1.31–7.35)          | 0.01                           | 2.72 (1.10–6.71)              | 0.029   |
| Metaplasia           | Age between 41 and 50 years | 7.6 (2.76–20.92)         | 0.001                          | 7.31 (2.63–20.29)             | 0.001   |
|                      | Age between 51 and 60 years | 10.18 (3.77–27.47)        | 0.001                          | 8.75 (3.22–23.79)             | 0.001   |
|                      | Age ≥61 years     | 21.00 (8.01–55.00)          | 0.001                          | 20.00 (7.57–52.84)            | 0.001   |
|                      | NSAID consumption | 0.35 (0.19–0.66)            | 0.001                          | 0.37 (0.19–0.71)              | 0.003   |
|                      | \textit{H. pylori} infection | 3.94 (1.67–9.27)         | 0.002                          | 3.58 (1.47–8.72)              | 0.005   |
| Dysplasia            | Age between 41 and 50 years | 15.77 (3.56–69.87)        | 0.001                          | 16.29 (3.66–72.38)            | 0.001   |
|                      | Age between 51 and 60 years | 8.40 (1.78–39.57)        | 0.013                          | 7.65 (1.62–36.11)             | 0.013   |
|                      | Age ≥61 years     | 19.45 (4.44–85.11)          | 0.001                          | 18.64 (4.25–81.79)            | 0.001   |
|                      | NSAID consumption | 0.33 (0.13–0.80)            | 0.014                          | 0.33 (0.13–0.82)              | 0.017   |

**OR** odds ratio
metaplasia are considered the main precancerous conditions of the stomach and they develop, although slowly, during continuous \textit{H. pylori} infection \cite{30}, that is therefore claimed to be a crucial risk factor of gastric cancer, especially outside the cardia \cite{1}. The presence of precancerous conditions in dyspeptic patients in our study is in line with other studies in Iran but not as common as that reported by studies of Chinese and Asian cases \cite{31–33}; however, it is more frequent than what is reported in western countries \cite{34–36}.

Although the gold standard for \textit{H. pylori} detection is gastric biopsy, a study in Mashhad, Iran has shown detection of this infection in 698 out of 814 (85.75\%) patients by the urea breath test (UBT) \cite{37}, which is just slightly higher than our results. In Ardabil, a high-risk region of gastric cancer in north-western Iran, histological results for \textit{H. pylori} were found positive in almost 90\% of the cases examined \cite{14}. As exemplified by a report of 589 positive cases out of 736 (80.0\%) examined dyspeptic patients in Mongolia, a country known for its high rates of gastric cancer mortality \cite{38}, this infection is indeed common.

The high prevalence of \textit{H. pylori} infections in Iran is an important point due to the overwhelming evidence of a connection between this bacterium and cancer of the stomach. The mechanism involved seems have to do with \textit{H. pylori} inducing over-expression of COX-2, a cyclooxygenase enzyme that catalyses the conversion of arachidonic acid into prostaglandins, higher levels of which have been found in gastric carcinoma and precancerous conditions \cite{39, 40}. COX-2 expression is positively associated with histological status \cite{41–43}, and the COX-2/prostaglandin pathway induced by \textit{H. pylori} almost certainly plays an important role in gastric carcinogenesis \cite{44–47}. The drug celecoxib has been shown to inhibit both the flagellar movement and colonization of the \textit{H. pylori} bacterium, and a recent population-based study reveals that treatment with this drug has beneficial effects on advanced gastric conditions \cite{48}. Other studies have shown that the drug can significantly reduce the risk of cancer of the colon, lung, breast and prostate \cite{49–51}.

Screening and treatment of \textit{H. pylori} should be encouraged, especially in north-eastern Iran as both \textit{H. pylori} infection and gastric cancer are common in this region \cite{52}. As found in the present study, it is important to consider presence of \textit{H. pylori} infection in the stomach of dyspeptic patients even with normal macroscopic results. That biopsies facilitate the diagnostic approach is further emphasized in a study showing \textit{H. pylori} infection in 50\% of normal-appearing gastric mucosa \cite{24}, and AGA recommends taking biopsies also of normal-appearing body and antrum of the stomach to explore this potential \cite{15}. In consequence with this strong evidence, we feel that EGD alone is not sufficient for detecting all kinds of \textit{H. pylori}-related inflammatory and precancerous gastric conditions in dyspeptic patients. However, studies on cost versus benefit of regularly adding biopsy studies are needed to complement current findings \cite{53, 54}.

The prevalence is affected by many factors, e.g., residency, ethnicity, age, socioeconomic aspects \cite{55, 56}, living conditions, lifestyle, hygiene status and industrialization \cite{57–59}. Smoking is an independent risk factor for different types of gastrointestinal cancers and previous studies in Iran have revealed direct links between smoking and cancers \cite{27, 60}. However, this study did not reach anywhere near statistical significance between smoking and precancerous stomach conditions; on the other hand, this could be due to the relatively low number of smokers in the cohort examined. Interestingly, regular use of NSAID was found to be negatively associated with appearance of this kind of conditions and so was aspirin but not at a significant level; again possibly due to the low number of regular aspirin takers in the cohort. A few cohort studies have also reported that NSAIDs consumption is associated with a reduced risk of gastrointestinal cancers, including gastric cancer \cite{61, 62}. However, large-scale, clinical trials are needed to recommend it as protective for gastric cancer. The wider use of the drug celecoxib can also be contemplated, but here we need diagnosis before treatment. Indeed, the widespread use of drugs is fraught with unforeseen side effects and should not be advocated without strong backing evidence.

Two studies in Ardabil, a high-incidence gastric cancer province in Iran, revealed that opium use, water pipe inhalation and high salt intake are risk factors for this cancer \cite{14, 63}. Also in our study, \textit{H. pylori} infection was more common in patients addicted to opium. Further, opium addiction was more common in patients with intestinal metaplasia and dysplasia, although regression analysis revealed no significant association between them. The association between opium use and human cancer have been discussed for a long time with different mechanisms suggested. For example, there is some evidence that opium could increase the ethylation of DNA through reduction of N-nitrosamines and N-nitrosodimethylamine \cite{64}. Also, it has been shown that opiates could work as cancer promoters by damaging human immune function, activating angiogenesis and tumour neovascularisation and also increasing N-nitrosamines and related materials by changing pharmacokinetics \cite{64}. Furthermore, since addicted people often do not keep a personal high hygiene status, \textit{H. pylori} infection may be more...
common among them. In spite of this collected evidence, a clear cause effect study is needed to confirm this association.

Our study had some limitations. First, Information about proton pump inhibitor (PPI) consumption was not available in this study. Some patients had previous use of PPI and some were frequently self-medicated, so they could not discontinue PPI for an adequate period before endoscopy. Although consistent with previous studies [65, 66] and AGA guidelines [15] we obtained biopsies both from antrum and body for the detection of \textit{H. pylori} infection, but PPI consumption may reduce the colonization density of \textit{H. pylori} and leads to false negative results at the histopathology assessment [67]. Second, the quantitative measurements of opium and alcohol abuse as well as use of NSAIDs and aspirin or other drugs were not addressed in the study. Furthermore, due to the high cost of pathology in our setting, we followed the AGA guidelines [15] and put all the samples together. Thus, it is not possible to classify according to the Sydney system, because in this system, a biopsy should be taken separately from body, antrum, and incisura. However, if precancerous conditions were found in the endoscopy surveillance, separate samples should be taken from different gastric locations. However, although this was not the aim of the current study, this kind of surveillance should be addressed by future studies. These limitations impose a lack of generalizability of the findings, but we still think it will be useful for low-and middle-income countries especially in the Middle East where there is a restriction of the resources available like in Iran.

**Conclusion**

This study shows that endoscopic biopsies, even from normal-appearing gastric mucosa, increase the chance of finding gastric cancer at the precancerous stage especially in patients infected with \textit{H. pylori}. There is a well-supported connection between \textit{H. pylori} infection and precancerous and cancerous conditions and as this infection is unusually common in parts of Iran, large-scale national screening may be beneficial. Finding patients at an early stage would save lives and reduce costs.

**Acknowledgments**

We would like to thank Mashhad University of Medical Sciences for its support.

**Authors’ contributions**

AE, LG, BH, and MBO contributed to the study design. All authors (AE, LG, RB, AF, AKh, LJ, HMM, AB, MBO, and BH) contributed to data gathering and interpretation of the results. LJ and BH performed analyses. BH, MBO, and LG wrote the first draft of the manuscript. RB edited the final version of the manuscript. All authors (AE, LG, RB, AF, AKh, LJ, HMM, AB, MBO, and BH) read, commented, and approved the final manuscript.

**Funding**

This study was supported by Mashhad University of Medical Sciences (grant number of 941-480). The funder had no role in design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are available in the Harvard Dataverse repository, [https://doi.org/10.7910/DVN/RVQZDG](https://doi.org/10.7910/DVN/RVQZDG).

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Ethics committee of Mashhad University of Medical Sciences (ethics code: IR.MUMS.fm.REC.1395.132). Written informed consent was obtained from all participants. All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Ingerod, SE-454 94, Brastad, Sweden. 4. Formerly UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland. 5. Community Medicine Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Cardiology Resident, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 8. Department of Internal Medicine, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. 9. Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 10. Department of Health Information Technology, Neyshabur University of Medical Sciences, Neyshabur, Iran.

**Received:** 18 January 2021 **Accepted:** 26 July 2021 **Published online:** 26 October 2021

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. [https://doi.org/10.3322/caac.21492](https://doi.org/10.3322/caac.21492) Epub 2018/09/13. PubMed PMID: 30207599.

2. Almasi Z, Mohammadian-Hafshejani A, Salehinia H. Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. J BUON. 2016;21(4):994–1004 Epub 2016/09/30. PubMed PMID: 27685925.

3. Esmaeizadeh A, Hoseini B, Yousefli Z, Khooie A, Etminani K, Esmaeilzadeh A, et al. Predictive model for survival in patients with gastric cancer. Electron Physician. 2017;5(12):6035–42. [https://doi.org/10.19082/6035](https://doi.org/10.19082/6035) Epub 2018/03/22. PubMed PMID: 29560157; PubMed Central PMCID: PMCPMC5843431.

4. Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol. 2003;36(5 Suppl):S29–36; discussion S61-2. [https://doi.org/10.1097/00005836-200305000-00006](https://doi.org/10.1097/00005836-200305000-00006) Epub 2003/04/19. PubMed PMID: 12702963.

5. Cameiro F, Machado JC, David L, Reis C, Nogueira AM, Sobrinho-Simões M. Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev. 2001;10(1):101–2. [https://doi.org/10.1097/00008469-200102000-00013](https://doi.org/10.1097/00008469-200102000-00013) Epub 2001/03/27. PubMed PMID: 11263582.

6. Pimentel-Nunes P, Dinis-Ribeiro M. Endoscopic submucosal dissection in the treatment of gastrointestinal superficial lesions: follow the guidelines! GE
